retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Retatrutide (Eli Lilly's triple GLP-1 Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article.
The Bottom Line GLP-1 agonists are powerful and effective medications for Type 2 diabetes and obesity
Pricing shown is for presentation and consultation flow purposes
Future Directions Recently, Sundaram presented the results of PRAISE HFpEF DM
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks
4 The labels for GLP-1 receptor agonists do not directly contraindicate their use in patients with a history of pancreatitis
